Ascendis Pharma (NASDAQ:ASND) initiated with Outperform rating with a $199 (97% upside) price target at Oppenheimer.
Livongo Health (NASDAQ:LVGO) initiated with Buy rating and $30 (39% upside) price target at Stifel.
New Frontier Health (NFH) initiated with Outperform rating at Credit Suisse.
Cardinal Health (NYSE:CAH) upgraded to Buy with a $58 (32% upside) price target at Bank of America. Shares up 3% premarket.
Community Healthcare Trust (NYSE:CHCT) upgraded to Buy with a $40 (43% upside) price target at B. Riley FBR.
Gilead Sciences (NASDAQ:GILD)
upgraded to Overweight with a $90 (15% upside) at Piper Sandler in
anticipation of the FDA nod for remdesivir for COVID-19. Shares up 4% premarket.
Pacira BioSciences (NASDAQ:PCRX) upgraded to Outperform with a $44 (35% upside) price target at SVB Leerink.
Perrigo (NYSE:PRGO) upgraded to Outperform with a $52 (19% upside) price target at SVB Leerink.
UnitedHealth Group (NYSE:UNH) upgraded to Buy with a $308 (40% upside) price target at Deutsche Bank. Shares up 6% premarket.
https://seekingalpha.com/news/3553689-piper-sandler-likes-gilead-ahead-of-expected-fda-nod-for-remdesivir-for-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.